Breakthrough Therapy Shows Promising Long-Term Results for Depression
Source: Streetwise Reports  (11/19/24)
Cybin Inc. (CYBN:NYSE American; CYBN:NEO) has announced positive results from its 12-month Phase 2 study of CYB003, a proprietary deuterated psilocin program designed for the adjunctive treatment of major depressive disorder (MDD). Find out about the FDA's designation of this treatment and why the Chief Medical Officer sees this news as "highly encouraging." More >

Chicago Alt. Medicine Co. Announces US$50M Share Repurchase Program
Source: Nick Anderson  (6/18/24)
In a Roth MKM research note, analyst Nick Anderson noted that Verano Holdings Corp. (VRNO:CSE; VRNOF:OTCQX) was well-positioned to generate increasing cash flow. More >

Critical Reforms Stuck in Congressional Gridlock
Source: McAlinden Research  (5/7/24)
McAlinden Research shares its thoughts on the current state of the cannabis market in light of recent legislative moves and two ETFs that may be impacted. More >

Wellness Co. Preparing for US Legislation
Source: Bill Kirk  (2/12/24)
Wellness company Canopy Growth Corp. is taking steps forward while it waits for the U.S. to make legislative changes, according to a Roth MKM research note. More >

Drug Reformer Subsidiary Inspected for Dealer License
Source: Streetwise Reports  (2/2/24)
In a "transformative moment" for the company, a Safe Supply Streaming Co. Ltd. subsidiary has undergone an official inspection by Health Canada to acquire a dealer license to produce, distribute, and export controlled substances. More >

Innovator in Drug Policy Now Listed on the OTCQBA Venture Market
Source: Streetwise Reports  (1/18/24)
Safe Supply Streaming Co. Ltd. Announced that it is expanding availability for potential investors. Read on to see why this stock might represent an opportunity as drug policy changes. More >

Pharma Co. Invests in Clinical Psychedelics
Source: Streetwise Reports  (1/17/24)
ATAI Life Sciences N.V. has announced that it is investing in psychedelic treatments for Major Depressive Disorder and Alcohol Use Disorder. Read on to see why one analyst likes this company's stock. More >

Pharma Co. Gets First US Patent for Repurposed Drug
Source: Streetwise Reports  (1/2/24)
Clinical-stage pharmaceuticals firm Algernon Pharmaceuticals Inc. has been issued a U.S. patent for the treatment of three related diseases with its investigational drug repirinast. More >

Lithium Co. Will Be a Substantial Outperformer
Source: Michael Ballanger  (12/19/23)
Michael Ballanger of GGM Advisory Inc. shares a quick note about why he has faith in Volt Lithium Corp. More >

Drug Reform Streaming Co. Starts Trading on CSE
Source: Streetwise Reports  (10/12/23)
This company investing in and incubating companies at the forefront of drug policy reform has started trading on the Canadian Securities Exchange. One writer says buying stock is a chance to be a part of a "movement." More >

Biotech Co. Makes Strides on Three Fronts
Source: Andrew Partheniou  (9/19/23)
This Canadian firm sold assets, launched an equity raise and filed a clinical trial application for its lead psychedelic-assisted psychotherapy program, noted a Stifel report. More >

Co. Still Undervalued Post Solid Q2/23
Source: Scott Fortune  (8/16/23)
The multistate operator is on a growth trend and just raised its free cash flow guidance for the year, noted a ROTH Capital Partners report. More >

Co. Works to Strengthen Itself After Merger Ended
Source: Scott Fortune  (8/2/23)
Its efforts include restructuring debt and divesting assets, noted a ROTH Capital Partners report. More >

Merger Between Two Firms Called Off
Source: Scott Fortune  (8/2/23)
The deal broke down because the parties could not sell assets that had to be divested for it to go through, noted a ROTH Capital Partners report. More >

Second Half of 2023 Is Catalyst Rich for This Biopharma Co.
Source: Patrick Trucchio  (7/19/23)
The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant depression, noted an H.C. Wainwright & Co. report. More >

Biotech Co. Completes Step Toward Psychedelic Treatment for Brain Injuries
Source: Streetwise Reports  (6/16/23)
Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream. More >

Court Grants Firm Protection From Creditors
Source: Andrew Semple  (6/12/23)
Despite this development, there are still some ways this Canadian retailer-distributor could salvage some value for shareholders, noted an Echelon Capital Markets report. More >

U.S. Firm's Earnings To Remain Robust Through 2023
Source: Andrew Semple   (5/25/23)
Recent and upcoming events, including new store openings, will drive sales and revenue growth for this retailer and wholesaler, noted an Echelon Capital Markets report. More >

Wellness Co.'s Q1/23 Results Better Than Expected
Source: Andrew Semple  (5/19/23)
Results for the first quarter of this year for Ayr Wellness Inc. were better than expected, reported an Echelon Capital Markets research note. More >

Adding Silver a Solid Move
Source: Michael Ballanger  (4/24/23)
Michael Ballanger of GGM Advisory Inc. reviews the state of the SPX Index, the gold-to-silver ratio, and the current lithium market. More >

Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial
Source: Streetwise Reports  (4/19/23)
Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill. More >

Blockchain Co., Vets Group Team Up for App
Source: Streetwise Reports  (4/19/23)
A Vancouver blockchain company is partnering with a leading veterans advocacy group to launch a medical cannabis education and reward application for vets. More >

Biotech Co. Set To Reach New Highs
Source: Streetwise Reports  (4/13/23)
Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics. More >

Firm Grows Revenue 38% in Q4/22
Source: Andrew Semple  (4/4/23)
The company's material increase in profitability during the quarter is a healthy step toward reaching free cash flow break even status, noted an Echelon Capital Markets report. More >

Former NFL Safety Director Joins Neurotherapy Firm Advisory Board
Source: Streetwise Reports  (3/21/23)
Treating traumatic brain injury with alternative pharmaceuticals is delicate work. Now one Canadian firm has enlisted the help of former National Football League Neurological Player Care Safety Director Dr. David Brody. More >